NEW YORK, April 2 – Dutch proteomics company Glaucus Proteomics has entered into a deal to gain access to Medarex’ and Genmab’s antibody technology in exchange for novel targets and shared rights to future therapeutic products, the companies said Monday.
“We provide the antibody technology to Glaucus and they are going to find diagnostics and research uses for antibodies. And using their antibody reporter matrix they will find new disease targets that we can make antibodies against,” Lisa Drakeman, CEO of Genmab, told GenomeWeb.
Glaucus will use Medarex's HuMAb-Mouse technology to build a warehouse of fully human antibodies that will be used to construct an antibody reporter matrix. Glaucus expects to use the matrix for signature profiling of human tissues in health and disease via chip-based differential analysis of protein expression levels. This process will be similar to a cDNA biochip, but will be directed at proteins.
In exchange for the rights to use fully human antibodies in connection with its proteomics technology, Glaucus will provide all the novel targets it discovers through its own research efforts using the HuMAb technology to the collaboration.
"With Medarex and Genmab, we intend to transform a powerful enabling technology in proteomics that is centered on target discovery into one which is also linked to a drug warehouse of pre-screened fully human antibodies," Ian Humphery-Smith, chief operating officer of Glaucus, said in a statement. "For us, it is of paramount importance to access the highest quality antibodies from the outset of a program designed to raise antibodies against the constituents of the human proteome.”
Under the terms of the deal, Glaucus will have 50 percent of the rights to any future therapeutic products while Genmab and Medarex will share the remaining 50 percent.
Medarex of Princeton, NJ, owns 33 percent of Genmab, which is based in Copenhagen.